| 1.925 0.275 (16.67%) | 10-09 15:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.44  |
1-year : | 2.85 |
| Resists | First : | 2.09 |
Second : | 2.44 |
| Pivot price | 1.5 |
|||
| Supports | First : | 1.54 |
Second : | 1.2 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.46 |
| MA(100) : | 1.64  |
MA(250) : | 3.1 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 77 |
D(3) : | 65.1 |
| RSI | RSI(14): 69.4 |
|||
| 52-week | High : | 7.07 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TELO ] has closed above the upper band by 15.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 11.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.55 - 1.56 | 1.56 - 1.57 |
| Close: | 1.63 - 1.65 | 1.65 - 1.66 |
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Thu, 09 Oct 2025
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Thu, 09 Oct 2025
Telomir Pharma’s Cutting-Edge Cancer Breakthrough - StocksToTrade
Thu, 09 Oct 2025
Telomir’s Investigational Therapy: A Game Changer? - timothysykes.com
Wed, 08 Oct 2025
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - inkl
Mon, 06 Oct 2025
Telomir Pharmaceuticals Announces Promising Preclinical Findings - TipRanks
Thu, 04 Sep 2025
Telomir Pharmaceuticals raises $2.9 million through at-the-market stock sale - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 1.946e+007 (%) |
| Held by Institutions | 37 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -687 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.89e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|